Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-03-23

Clinical Trial Update: Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC) [Phase 2]

View source ↗

Summary

Phase 2 trial of sunitinib malate in metastatic or surgically unresectable hepatocellular carcinoma was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sutent (sunitinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Liver Cancer | Phase 2 | Status: TERMINATED | Results posted: 2012-03-23